Gain Therapeutics, Inc.
GANX
$1.72
-$0.11-6.01%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -4.68M | -5.61M | -4.54M | -5.28M | -5.81M |
| Total Depreciation and Amortization | 14.20K | 9.30K | 15.20K | 10.80K | 9.30K |
| Total Amortization of Deferred Charges | 13.00K | 12.00K | 13.00K | 12.00K | 13.00K |
| Total Other Non-Cash Items | 666.00K | 634.00K | 412.90K | 470.90K | 1.20M |
| Change in Net Operating Assets | -697.60K | 225.90K | -522.00K | -135.70K | -507.50K |
| Cash from Operations | -4.68M | -4.73M | -4.62M | -4.93M | -5.10M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -25.30K | -25.50K | -25.00K | -25.00K | -24.20K |
| Issuance of Common Stock | 1.39M | 429.80K | 16.58M | 7.45M | 2.49M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | -395.50K | -- |
| Cash from Financing | 1.37M | 404.30K | 16.55M | 7.03M | 2.47M |
| Foreign Exchange rate Adjustments | -141.60K | 24.60K | 97.80K | 6.70K | 260.10K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.46M | -4.30M | 12.03M | 2.11M | -2.37M |